Paper Details

  1. Home
  2. Paper Details

Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan.

Author: BrodM I, ColmanS S, Gomez-MancillaB, JirgensK J, KrishnamurthyA, RowlandC R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that almotriptan was associated with significantly greater satisfaction with the side-effect profile of the drug than sumatriptan in patients with migraine. There were no significant differences between the two groups in terms of satisfaction with pain relief, functional status, or health-related quality of life.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Patient-reported outcomes, such as treatment satisfaction, functional status, and health-related quality of life (HRQOL) are essential components of migraine research. Almotriptan is a new selective serotonin 1B/1D agonist triptan migraine treatment. OBJECTIVE: The purpose of this doubl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0149-2918(01)80036-9

データ提供：米国国立医学図書館（NLM）

Almotriptan vs. Sumatriptan: A Head-to-Head Comparison for Migraine Treatment

Migraines are a debilitating condition that can significantly impact quality of life. This study investigates the effectiveness and safety of two triptan medications, almotriptan and sumatriptan, in treating migraine headaches. The researchers conducted a double-blind, randomized, parallel-group study to compare the two drugs' ability to alleviate migraine symptoms and improve patient satisfaction.

Almotriptan: A More Tolerable Option for Migraine Relief

The study found that almotriptan was associated with significantly greater patient satisfaction regarding side effects compared to sumatriptan. Patients taking almotriptan reported fewer side effects and were more satisfied with their overall experience. This finding suggests that almotriptan may be a more tolerable option for migraine patients, particularly those who are sensitive to the side effects of sumatriptan.

Navigating the Triptan Landscape

The study highlights the importance of considering individual patient needs and preferences when choosing a migraine medication. While both almotriptan and sumatriptan are effective in treating migraine headaches, almotriptan may be a better choice for patients who are concerned about side effects. It's like choosing a route through the desert – one path might be smoother and more comfortable, while another offers a more challenging but potentially rewarding journey.

Dr.Camel's Conclusion

This study provides valuable insights into the relative tolerability of almotriptan and sumatriptan for migraine treatment. Almotriptan emerged as the more tolerable option, with patients experiencing fewer side effects and reporting greater satisfaction. However, it's important to note that this study was conducted with a specific population of patients, and further research is needed to confirm these findings in a broader population.

Date :
  1. Date Completed 2001-04-19
  2. Date Revised 2019-09-21
Further Info :

Pubmed ID

11219473

DOI: Digital Object Identifier

10.1016/s0149-2918(01)80036-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.